Both Cassetty and Bragagnini also stress the importance of upping your water intake as you consume more fiber. As Cassetty puts it, “fiber is thirsty.” It requires ample hydration to slip through your ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. GLP-1 agonist drugs like Ozempic and Wegovy have surged in popularity during the last ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

8-10 strawberries, 3-4 slices of ginger, one slice of lemon, one slice of orange, one of beetroot, two and a half litres of water, and 4-5 tablespoons of honey.

The Kansas City Chiefs are on the brink of NFL history as they aim for a third consecutive Super Bowl victory. The team is gearing up for another showdown against the Philadelphia Eagles ...

Victory in Garmisch, 2nd places in Beaver Creek, St. Moritz and Cortina and 5th place in St. Anton - Lara Gut-Behrami's super-G results this World Cup winter speak for themselves. But in the World ...

(MENAFN- PR Newswire) "GLP-1 medications are truly a breakthrough in weight management, but they can also create significant nutrient gaps in things like vitamin B12, vitamin D, iron and calcium ...

Combine beetroot, cucumber, and fresh mint leaves. Add a splash of lime juice for an extra zing, making this an ideal drink for hot days It combines the earthiness of beetroot with the freshness ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased year over year, as well as greater insulin and Rare disease sales.